Jin Medical closes US$159.42 million VIE control acquisition of Huaxia Qiying
ZJYL•Jin Medical completed its VIE-control acquisition of Huaxia Qiying on Sept. 24, 2026, for aggregate consideration of US$159.42 million, including 71,282,488 Class A shares and non-share assets and interests.
1. Acquisition closed
The acquisition was completed through Erhua Medical Technology (Changzhou). Jin Medical also paid a separate advisory fee in 8,479,560 Class A shares to Veltrion Haskel Holdings and designee Quinnet Section. After closing, the company had 158,194,533 shares outstanding: 153,425,476 Class A shares and 4,769,057 Class B shares. A Kangma Equity transfer is targeted by Sept. 30, 2026; if it is not completed by Oct. 31, 622,123 Class A shares will be issued as a substitute.
